Abstract: The present invention relates to agricultural methods and the use of an insecticidal active carboxamide derivative in seed treatment and soil application methods. The insecticidal carboxamide derivative is highly suitable alone or in combination with other active agricultural ingredients for controlling animal pests such as insects and/or spider mites and/or nematodes by treating the soil/growth substrate by drenching or drip application or dipping or soil injection.

Abstract: The present invention is directed to an aqueous composition comprising spirotetramat, pyriproxyfen, a solvent system comprising heavy aromatic naphtha, cottonseed oil and optionally, acetyl tributyl citrate, one or more poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) block copolymers and an acrylic type co-polymer having a backbone containing a carboxylated ethylenically unsaturated monomer and a non-carboxylated ethylenically unsaturated monomer and water. The present invention is further directed to methods of controlling pests by applying the compositions of the invention to an area in need thereof.

Abstract: This invention relates to compositions for combating ectoparasites and endoparasites in animals, comprising eprinomectin and praziquantel in combination with a pharmaceutically acceptable carrier, and optionally an antioxidant. This invention also provides for an improved methods for eradicating, controlling, and preventing parasite infections and infestations in an animal comprising administering the compositions of the invention to the animal in need thereof.

Abstract: According to one broad aspect of this disclosure, a method is provided for producing polyhydroxyalkanoates (PHA) from organic waste. The method comprises homogenizing organic waste to obtain a feedstock that has 1:1 to 3:1 (w/w) water to organic waste ratio. The feedstock is inoculated with an inoculum of acidogenic fermentative bacteria in order to obtain an inoculated feedstock. The inoculated feedstock is incubated for 5 to 10 days, 3 to 10 days, optionally 7 days, optionally 3 days, to obtain a fermentation broth. The fermentation broth comprises volatile fatty acids (VFAs) and undigested organic waste. The fermentation broth is filtered with a filter with a pore size ranging from 0.2 ?m to 500,000 NMWC to remove the acidogenic fermentative bacteria and undigested organic waste, to obtain a clarified broth comprising concentrated VFAs. The clarified broth and high-PHA producing bacteria are incubated to produce intracellular PHA granules in the high-PHA producing bacteria.

Abstract: Embodiments include formulations and methods for topical administration of sugar alcohol to treat a skin condition such as acne. A formulation can include a moisturizer, an emollient, a sugar alcohol and zinc. The sugar alcohol can be erythritol. The erythritol can be administered with zinc chloride. The erythritol and zinc chloride can be formulated at a molar ratio of about 3:1. The methods can also include administration of a therapeutic amount of a second agent such as benzoyl peroxide or a retinoid.

Abstract: A single-dose oral formulation of spinosad and lufenuron and methods for its use in the extended control of a flea infestation on a domestic animal such as a dog without emesis.

Abstract: Injectable Ivermectin solution is safely administrable to humans and animals used the disclosed technology. A macrocyclic lactone cyclodextrin complex which is completely dissolvable or dissolved in water in a ratio of at least 50 micrograms to 500 milligrams of the macrocyclic lactone complex per 5 milliliters of water. The macrocyclic lactone cyclodextrin complex is non-toxic, without using organic solvents, and in embodiments, formed by adding a surfactant to the macrocyclic lactone complex to water. The macrocyclic lactone cyclodextrin complex is Ivermectin or an Ivermectin derivative in some embodiments. The cyclodextrin complex is 2-hydroxypropyl-beta-cyclodextrin in some embodiments of the disclosed technology. The surfactant can be polysorbate 80 and is in a ratio of 0.01% to 25%, by weight, to said water. The water soluble complexes can be added to the water. The water-soluble complexes can have at least one of an anti-parasitic, anti-viral and anti-cancer complex.

Abstract: The present invention relates to the use of avermectin derivative as a drug for the treatment of parasitic infections. The avermectin derivative is represented by the formula (I) wherein: (i) R1 is chosen from the group constituted of —CH(CH3)2, —CH(CH3)CH2CH3, or cyclohexyl, (ii) X represents —CH2—CH2—, or —CH?CH—, (iii) R2 is chosen from or an OH group, (iv) R3 is OH or NOH, (v) represents a single bond when R3 is OH, or a double bond when R3 is NOH, as an inhibitor of a membrane-bound protein which transports exogenous compounds out of target cells.

Abstract: The present invention relates to a process to improve the yield of strawberry crops, the process comprising the step of applying a polyene antifungal agent, especially natamycin, to the roots of a strawberry plant prior to planting said plant and/or to the medium to which the plant is to be planted. The claimed process results in an increased number of crop, an increase in the weight of individual crop, and an increase in the total weight of the crop, and may allow for an earlier harvest.

Abstract: This application is directed to a homogeneous solution of an aqueous, topical composition useful for the treatment of infection and/or for the treatment of inflammation due to trauma to tissue. Specifically, this application relates to a homogeneous, aqueous composition of a quinolone antibiotic and an anti-inflammatory agent.

Abstract: A monodose veterinary composition for topical application (spot on) for canines, the said composition comprising: (a) Imidacloprid, between 8.18 and 10.00%, (b) Moxidectin, between 2.86 and 3.50%, (c) Praziquantel, between 8.18 and 10.00%, and (d) an aprotic solvent selected from Dimethyl sulfoxide (DMSO), N,N-dimethylacetamide (DMAC), N,N-dimethylformamide (DMF) and their mixtures, between 65.45 and 80.00%; together with excipients acceptable from the veterinary viewpoint, where the percentages are related to the composition's total weight.

Abstract: Methods of administering a composition that comprises plant extracts selected from the group consisting of Quercus infectoria, Rhus chinensis and Terminalia chebula containing compounds such as gallic acid, derivative of gallic acid, gallotannins and hydrosable tannins, which have been found to control coccidiosis in poultry and, more specifically, coccidiosis caused by Eimeria spp. The plant extracts result in a reduction of lesion score, oocysts per gram of fecal matter and mortality.

Abstract: Natural plant parts and extracts of plants selected from the group consisting of Quercus infectoria, Rhus chinensis and Terminalia chebula containing compounds such as gallic acid, derivative of gallic acid, gallotannins and hydrolysable tannins have been found to control coccidiosis in poultry and, more specifically, coccidiosis caused by Eimeria spp. The plant parts and natural extracts result in a reduction of lesion score, oocysts per gram of fecal matter and mortality.

Abstract: In alternative embodiments, the invention provides a “triple combination” therapy for treating, ameliorating and preventing Crohn's Disease (or Crohn syndrome, terminal or distal ileitis or regional enteritis) or related disorders and conditions in mammals, such as paratuberculosis in mammals, or Johne's disease, including genetically-predisposed and chronic disorders, where the microbial or bacterial flora of the bowel is at least one causative or symptom-producing factor; and compositions for practicing same. In alternative embodiments, methods and compositions of the invention comprise or comprise use of therapies, medications, formulations and pharmaceuticals comprising active agents that can suppress or eradicate the microbiota super-infection that causes Crohn's Disease or paratuberculosis infection in mammals.

Abstract: Embodiments of the invention relate to methods and systems for the detection of Mycobacterium tuberculosis. Mycobacterium tuberculosis kills more than one million people each year. To better understand why M. tuberculosis is virulent and to discover chemical markers of this pathogen, we compared its lipid profile to that of the attenuated but related mycobacterium, Mycobacterium bovis Bacille Calmette Guerin (BCG). This strategy identified previously unknown compounds that are specific to M. tuberculosis, e.g. 1-tuberculosinyladenosine, N6-tuberculosinyladenosine, and various tuberculosinyladenosines having mycolic acids, produced by the Rv3378c enzyme.

Abstract: Described herein are processes for the preparation of compounds of formula (I): and pharmaceutically acceptable salts, solvates, and hydrates thereof.

Abstract: The present invention is directed to use of a series of tri-aryl compounds and compositions comprising the same for the treatment of diabetes and disease conditions arising as a consequence of the same.

Abstract: The present application relates to compounded compositions, methods of making compounded compositions, and methods of using compounded compositions. For example, disclosed herein are compounded compositions and methods of making compounded compositions comprising one or more anti-infective agents such as mupirocin.

Abstract: There may be provided compositions of lipophilic pharmaceutical agents with improved solubility and stability. For example, there may be provided a non-aqueous composition that comprises a lipophilic pharmaceutical agent, and an amphiphilic polymeric solvent such as PEG400 but essentially free of organic solvents and non-solubilized particles. The composition may be further diluted with a desired aqueous diluent such as an infusion fluid for parenteral administration to a subject such as a human. The compositions may be useful for the treatment for diseases or conditions that are sensitive to lipophilic agents, such as infectious diseases, malignant or autoimmune diseases.

Abstract: Provided herein are methods of preparing macrolides by the coupling of an eastern and western half, followed by macrocyclization, to provide macrolides, including both known and novel macrolides. Intermediates in the synthesis of macrolides including the eastern and western halves are also provided. Pharmaceutical compositions and methods of treating infectious diseases and inflammatory conditions using the inventive macrolides are also provided. A general diastereoselective aldol methodology used in the synthesis of the western half is further provided.

Abstract: Described herein are macrolide and ketolide antibiotics and pharmaceutical compositions, methods, and uses thereof for treating diseases caused at least in party by resistant bacteria.

Abstract: The present invention relates to novel mixtures, to processes for preparing these compounds, to compositions comprising these mixtures, and to the use thereof as biologically active compounds, especially for control of harmful microorganisms or pests in crop protection and in the protection of materials and for enhancing plant health.

Abstract: To provide a therapeutic agent for gastrointestinal disorder such as diabetic gastroparesis. A postprandial gastrokinetic agent containing (A) ghrelin or a ghrelin agonist and (B) motilin or a motilin agonist as active ingredients, in which both the ingredients (A) and (B) are administered so as to act on the stomach after food intake.

Abstract: Methods for the treatment and/or prevention of a fungal infection in the pulmonary system of a subject in need thereof with caspofungin or a derivative thereof are disclosed herein.

Abstract: The present invention relates to novel fungicidal compound including an aminoglycoside analog having certain substituents at the 6 position of ring III that exhibit improved antifungal activity but possess minimal antibacterial properties in combination with fungicidal azoles. The aminoglycoside compounds are analogues of kanamycin A. Also provided are methods of synthesizing and methods of using the compounds of the present invention. The compounds of the present invention are useful in treating or preventing fungal disease.

Abstract: A method of treating hyperesthesia, paresthesia, dolor, and pruritus caused by an insect or arthropod sting or bite, or a skin contact with a noxious weed or plant is disclosed. The method includes topically applying a dermatological composition containing an avermectin compound to an affected area immediately after said sting or bite, or said skin contact occurs. The method further includes moistening the affected area first prior to application of the dermatological composition.

Abstract: Lyophilized daptomycin formulations having improved reconstitution times are provided. The lyophilized daptomycin formulations include an additive, which can be a pharmaceutically acceptable antioxidant, a pharmaceutically acceptable organic acid or a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable glucose derivative or a pharmaceutically acceptable salt thereof, or a combination thereof. Also provided are methods of methods of preparing the lyophilized daptomycin formulations, and methods of treating bacterial infections and treating or preventing biofilms by using the lyophilized daptomycin formulations.

Abstract: Described herein are formulations and methods for treating diseases caused by infectious pathogens, including mycobacterium avium complex, mycobacterium tuberculosis, Nocardia, Plasmodium falcium, and Plasmodium berghei.

Abstract: Administration of at least one compound of the family of the avermectins or of the family of the milbemycins, notably ivermectin, is useful for the treatment of ophthalmic pathologies, including ocular rosacea.

Abstract: The present invention relates to a liquid topical veterinary pharmaceutical composition consisting of fipronil, permethrin at high concentration and pyriproxyfen such that it does not crystallize when it is applied to the coat of an animal, and to the use thereof in the prevention and/or treatment of infestations of domestic animals by external parasites. The present invention also relates to the use of pyriproxyfen as an inhibitor of the crystallization of a liquid formulation comprising fipronil and permethrin at high concentration.

Abstract: The invention provides methods of treating or preventing malaria comprising administering to an animal an effective amount of a compound of formula (I): Q-Y—R1—R2 (I), wherein Q, Y, R1, and R2 are as described herein. Methods of inhibiting a plasmodial surface anion channel of a parasite in an animal are also provided. The invention also provides pharmaceutical compositions comprising a compound represented by formula (I) in combination with any one or more compounds represented by formulas II, V, and VI. Use of the pharmaceutical compositions for treating or preventing malaria or for inhibiting a plasmodial surface anion channel in animals including humans are also provided. Also provided by the invention are clag3 amino acid sequences and related nucleic acids, vectors, host cells, populations of cells, antibodies, and pharmaceutical compositions.

Abstract: This invention provides a single-dose oral formulation of spinosad for the extended control of a C. felis infestation on a cat at a predictable dose of spinosad that is suitable for administration once every 30 days (i.e., one month). The invention also provides methods of using the formulation of spinosad.

Abstract: The present invention refers to pharmaceutical formulations based on lipids for ophthalmic use comprising a phospholipid component composed of zwitterionic phospholipids of natural origin and an oily component composed of oils of natural origin emulsified in water. In particular, the invention refers to ophthalmic formulations useful, for example, for transporting drugs to the eye and in the treatment of ocular dryness, capable of restoring the lipid layer of the tear film. In particular, in a non-transitory but pathological situation such as the dry eye syndrome, such formulations also succeed in reducing the often-present inflammatory component.

Abstract: The invention relates to the use of a macrolide antibiotic, tylvalosin, as an anti-viral agent. Tylvalosin is particularly useful for the treatment of PRRSV.

Abstract: Provided is concentrated aqueous azithromycin formulation from about from about 2%-20%, and a method of making a concentrated aqueous azithromycin formulation which includes preparing and sterilizing a first solution comprising a strong base to form a sterilized solution, dissolving the azithromycin in an aqueous solution comprising an acid consisting essentially of a strong acid, and adding the aqueous solution comprising the strong acid to the sterilized solution comprising the strong base. The strong acid has a pKa less than about ?1.74 and the method is carried out without addition or use of a weak acid.

Abstract: The present invention relates to methods of preventing and/or treating Clostridium difficile infection (CDI) in a subject at high risk for developing CDI including subjects receiving antibiotic therapy for a different infection comprising administering to the subject an effective amount of the compounds described herein.

Abstract: According to the present invention, a plant disease control agent having a superior control effect on plant diseases at a low dose is provided. The plant disease control agent of the present invention includes at least one selected from tetrazolyl oxime derivatives represented by formula (I) and salts thereof, and at least one selected from the group consisting of imidacloprid, triflumizole, spinosad, hydroxy isoxazole, thiophanate-methyl, tricyclazole, clothianidin, benomyl, acetamiprid and salts thereof. In formula (I), X represents a C1-6 alkyl group or the like; n represents an integer of 0 to 5; Y represents a C1-6 alkyl group; Z represents a group represented by NHC(?O)-Q; Q represents a C1-8 alkoxy group or the like; R represents a halogen atom; m represents an integer of 0 to 3.

Abstract: The invention provides a method of overcoming resistance to at least one antibiotic in a multidrug resistant bacterium, said method comprising contacting said bacterium with an alginate oligomer together with the antibiotic. The multidrug resistant bacterium may be on an animate or inanimate surface and both medical and non-medical uses and methods are provided. In one aspect the invention provides an alginate oligomer for use together with at least one antibiotic in treating a subject infected, suspected to be infected, or at risk of infection, with a multidrug resistant bacterium to overcome resistance to the antibiotic in said multidrug resistant bacterium. In another aspect the method can be used to combat contamination of a site with multidrug resistant bacteria, e.g. for disinfection and cleaning purposes.

Abstract: A pesticidal composition comprises a synergistically effective amount of a nicotinic acetylcholine receptor (nAChR) allosteric activator compound and a pesticide selected from N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-ethyl-3-((3,3,3-trifluoropropyl)thio) propanamide (I), N-(3-chloro-1-(pyridine-3-yl)-1H-pyrazol-4-yl)-N-ethyl-3-((3,3,3-trifluoropropyl)sulfinyl) propanamide (II), or any agriculturally acceptable salt thereof. A method of controlling pests comprises applying the pesticidal composition near a population of pests. A method of protecting a plant from infestation and attack by insects comprises contacting the plant with the synergistic pesticidal composition.

Abstract: The novel active compound combinations of extracts from seeds of the neem tree and the active compounds of groups (B) to (F) listed in the description have very good insecticidal and acaricidal properties.

Abstract: Provided are novel methods and formulations for topically controlling ectoparasite infestations in animals using spinetoram or a pharmaceutically acceptable salt thereof.

Abstract: The present invention relates to a method for controlling insects comprising the steps of preparing a tankmix by mixing a larvicide and a liquid adjuvant, wherein the adjuvant is essentially free of the larvicide and contains at least 1 wt % polyorganosiloxane, and at least 20 wt % synthetic organic solvent; and applying the tankmix on a water surface. The invention further relates to a liquid adjuvant for preparing a larvicidal tankmix, wherein the adjuvant is essentially free of a larvicide and contains at least 1 wt % polyorganosiloxane, and at least 20 wt % synthetic organic solvent. Finally, it relates to a method for preparing said adjuvant, comprising mixing the polyorganosiloxan and the synthetic organic solvent.

Abstract: It has been determined that co-administration of a rifamycin and a switch-region inhibitor 1) results in synergistic antibacterial effects, enabling efficacy at low, subtoxic doses, and/or 2) results in a low spontaneous resistance frequency, enabling treatment of high-titer infections without treatment failure due to spontaneous resistance. Accordingly, certain embodiments provide composition comprising a rifamycin and a switch region inhibitor, as well as methods of use thereof.

Abstract: A first aspect of the invention is an agricultural composition comprising nanoparticles, an agrochemical active ingredient in the nanoparticles, and optionally (but in some embodiments preferably) a carrier for the nanoparticles. In some embodiments, the nanoparticles are viral particles or capsids, particularly plant viral particles or capsids. In some embodiments, the carrier comprises an inert or biodegradable carrier (e.g., a solid carrier) to which the nanoparticles are bound or in which the nanoparticles are suspended. In some embodiments, the carrier comprises inert or biodegradable polymer fibers.

Abstract: Pest controlling compositions exhibiting enhanced pesticidal activity levels are disclosed. In one embodiment, a composition includes at least one pesticide, at least one transition metal salt and least one proteinaceous material. In this embodiment, the composition exhibits enhanced pesticidal activity levels compared to a composition dissimilar only in not having the at least one transition metal salt and the at least one proteinaceous material.

Abstract: Provided are novel methods and formulations for topically controlling ectoparasite infestations in animals using spinetoram, or a pharmaceutically acceptable salt thereof.

Abstract: The invention provides methods for producing high resolution crystals of ribosomes and ribosomal subunits as well as crystals produced by such methods. The invention also provides high resolution structures of ribosomal subunits either alone or in combination with protein synthesis inhibitors. The invention provides methods for identifying ribosome-related ligands and methods for designing ligands with specific ribosome-binding properties as well as ligands that may act as protein synthesis inhibitors. Thus, the methods and compositions of the invention may be used to produce ligands that are designed to specifically kill or inhibit the growth of any target organism.

Abstract: Pest controlling compositions exhibiting enhanced pesticidal activity levels are disclosed. In one embodiment, a composition includes at least one pesticide, at least one proteinaceous material and at least one polymeric material. In this embodiment, the composition exhibits enhanced pesticidal activity levels compared to a composition dissimilar only in not having the at least one proteinaceous material and the at least one polymeric material. Still, alternative embodiment pesticide compositions exhibiting enhanced activity levels are disclosed.

Abstract: A Maillard reaction inhibitor which effectively inhibits the progress of a Maillard reaction in a living body, can be safely applied without adverse side effects, can be manufactured without any complicated process, a skin anti-aging agent, an anti-diabetic complication agent and foods and beverages using the same. The Maillard reaction inhibitor contains 50 to 90% by mass of polyphenol as an active ingredient. The Maillard reaction inhibitor has a potent Maillard reaction inhibitory activity in a living body and allows for the prevention and improvement of the various dysfunction of protein in a living body. Due to this activity, the Maillard reaction inhibitor suppresses aging and can prevent and/or treat diabetic complications. Furthermore, when the above-described tannin is mixed in foods and beverages containing collagen, it is possible to suppress the Maillard reaction in the foods and beverages to suppress the deterioration of the foods and beverages.

Abstract: A pesticidal mixture comprising as active ingredient a mixture of component A and component B, wherein component A is a compound of formula (I), in which Q is i or ii wherein X, Y and Z, m and n, A, G, and R, are as defined as in claim 1, and component B is a compound selected from the following insecticides: a), pymetrozine; b). a pyrethroid selected from the group consisting of cyhalothrin, lambda-cyhalothrin, gamma-cyhalothrin; c). a macrolide selected from the group consisting of abamectin, emamectin benzoate, and spinetoram; d). a diamide selected from the group consisting of chlorantraniliprole and cyantraniliprole; e). thiamethoxam; f). sulfoxaflor; g). cyenopyrafen. The present invention also relates to methods of using said mixtures for the control of plant pests.